Zimbabwe has turned down a significant US health deal valued at 367 million US dollars (£272m) over five years over the United States' request for confidential data.
This move came to light following a government memo from December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "unbalanced".
A government spokesman has since stated that the United States was demanding access to genetic material for scientific study and commercial gain but refused to guarantee the resulting advantages from future treatments.
"We must now begin the challenging and unfortunate task of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had provided more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for further dialogue to reach a agreement agreeable to both sides so the nation's vital HIV treatment initiative can be sustained.
Wider Implications
This development follows a comparable situation in Kenya, where a court suspended a similar health funding agreement following concerns were raised about the safety of citizens' health data.
Since resuming the presidency last year, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered assistance for the US government, but Trump argued its expenditure was "wasteful" and his government was seeking direct bilateral agreements to boost openness and accountability.
Based on reports, 16 nations in Africa have to date signed these new health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership might have yielded extraordinary advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently on antiretroviral therapy via American-funded initiatives," the Ambassador added.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Zimbabwe was being asked to share its biological resources and data indefinitely, without any equivalent guarantee of access to any scientific breakthroughs – such as new medicines or tests – that might result from that provided information," he stated.
"Effectively, our country would provide the raw materials for scientific discovery with no certainty that the final treatments would be available to our people if a new disease outbreak arise."
National Interest and International Frameworks
He also pointed out that the US's withdrawal from the global health body and its push of one-on-one health agreements were disrupting frameworks already set up via the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to deal with potential pandemics.
"This system is intended to guarantee that when a country contributes its samples, the benefits – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the resources to create them."
These objections regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We welcome continued dialogue with our American counterparts on how future collaboration could be structured in a way that honours the independence and interests of both nations."
Medical Community Reaction
Medical experts said it understood the official position, but urged that talks should continue since much of the country's HIV programmes depended on international support.
"If specific concerns exist, such as those involving data governance or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," the group said.
The halted deal emphasises the complex debate between accepting vital foreign assistance and safeguarding a country's data in an ever more data-driven world.